Antithrombotic Management for Transient Ischemic Attack and Ischemic Stroke (Other than Atrial Fibrillation)

作者：Easton J Donald^*

来源：Current Atherosclerosis Reports, 2011, 13(4): 314-320.

DOI：10.1007/s11883-011-0185-0

• Antithrombotic drugs
• Antiplatelet drugs
• Transient ischemic attack
• TIA
• Cerebral infarction
• Prasugrel
• TRITON-TIMI 38 trial
• Ticagrelor
• PLATO trial
• Cilostazol
• CSPS trial
• CSPS 2 trial
• P2Y12 receptor
• Cytochrome P-450 polymorphisms
• CYP2C19
• CYP2C19 genotype
• CLOSURE I trial
• ABCD2
• ABCD2I
• TIA risk

The new definition and risk stratification for transient ischemic attack (TIA) have clear implications for the urgency of evaluation and treatment. The optimal antithrombotic treatment for TIA is being intensively studied. New guidelines for prevention of non-cardioembolic stroke in patients with stroke or TIA recommend the use of antiplatelet agents rather than oral anticoagulation. New antiplatelet drugs are being used in cardiovascular patients, and their role in cerebrovascular patients is being studied. The impact of genetic CYP2C19 polymorphisms is becoming clarified in cardiovascular patients and it is likely these polymorphisms will affect the management of cerebrovascular patients. The results of trials of clopidogrel plus aspirin in patients with lacunar strokes and acute TIAs are forthcoming. The results of CLOSURE I, a study of a patent foramen ovale device closure trial for cryptogenic stroke or TIA, showed no differences in stroke or TIA at 2 years.

• 出版日期2011-8